Oncimmune Holdings Management
Management criteria checks 3/4
Oncimmune Holdings' CEO is Martin Gouldstone, appointed in Aug 2023, has a tenure of 1.33 years. directly owns 0.092% of the company’s shares, worth £15.30K. The average tenure of the management team and the board of directors is 4.9 years and 5.7 years respectively.
Key information
Martin Gouldstone
Chief executive officer
UK£21.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.09% |
| Management average tenure | 4.9yrs |
| Board average tenure | 5.7yrs |
Recent management updates
CEO
Martin Gouldstone (58 yo)
1.3yrs
Tenure
UK£21,000
Compensation
Mr. Martin John Gouldstone is Chief Executive Officer and Director of Oncimmune Holdings plc from August 1, 2023. He serves as an Independent Non-Executive Director of ValiRx Plc since April 22, 2024 and s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | UK£21.00k | 0.092% £ 15.2k | |
| COO, General Counsel & Company Secretary | 4.7yrs | UK£27.00k | no data | |
| Finance Director | 1.3yrs | no data | no data | |
| Chief Scientific Officer | 5.2yrs | no data | no data | |
| Head of Investor Relations | 5.4yrs | no data | no data | |
| Chief Commercial Officer of Asia | 8.3yrs | no data | no data |
4.9yrs
Average Tenure
Experienced Management: ONC's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | UK£21.00k | 0.092% £ 15.2k | |
| Non-executive Chairman | 2.4yrs | UK£100.00k | 0.14% £ 23.0k | |
| Independent Non-Executive Director | 1.9yrs | UK£15.00k | 1.33% £ 219.5k | |
| Member of Scientific Board | 5.7yrs | no data | no data | |
| Member of Scientific Board | 6yrs | no data | no data | |
| Member of Scientific Board | 6yrs | no data | no data | |
| Member of Scientific Board | 6yrs | no data | no data |
5.7yrs
Average Tenure
54yo
Average Age
Experienced Board: ONC's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 19:19 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/02/29 |
| Annual Earnings | 2023/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oncimmune Holdings plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Bardo | Berenberg |
| Stuart Harris | Cavendish |
| Emma Ulker | Zeus Capital Limited |